GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViewRay Inc (OTCPK:VRAYQ) » Definitions » COGS-to-Revenue

VRAYQ (ViewRay) COGS-to-Revenue : 1.06 (As of Mar. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ViewRay COGS-to-Revenue?

ViewRay's Cost of Goods Sold for the three months ended in Mar. 2023 was $24.0 Mil. Its Revenue for the three months ended in Mar. 2023 was $22.5 Mil.

ViewRay's COGS to Revenue for the three months ended in Mar. 2023 was 1.06.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ViewRay's Gross Margin % for the three months ended in Mar. 2023 was -6.35%.


ViewRay COGS-to-Revenue Historical Data

The historical data trend for ViewRay's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViewRay COGS-to-Revenue Chart

ViewRay Annual Data
Trend Nov13 Nov14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 1.06 1.07 1.00 0.90

ViewRay Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.95 0.83 0.87 1.06

ViewRay COGS-to-Revenue Calculation

ViewRay's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=92.161 / 102.206
=0.90

ViewRay's COGS to Revenue for the quarter that ended in Mar. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=23.964 / 22.534
=1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViewRay  (OTCPK:VRAYQ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ViewRay's Gross Margin % for the three months ended in Mar. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 23.964 / 22.534
=-6.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


ViewRay COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ViewRay's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ViewRay Business Description

Traded in Other Exchanges
N/A
Address
1099 18th Street, Suite 3000, Denver, CO, USA, 80202
ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Sanket Shah officer: SVP, General Counsel C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Farhad Fred Ebrahimi 10 percent owner 191 UNIVERSITY BLVD., #246, DENVER CO 80206
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Paul Jr Ziegler officer: Chief Commercial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Scott William Drake director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Adam Andrew Podbelski officer: SVP, Customer Services C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Jacob Edward Signoriello officer: Chief Financial Officer C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER CO 80202
James F. Dempsey director, officer: Chief Scientific Officer C/O VIEWRAY INCORPORATED, 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Burke William P. Mr. officer: Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Susan C Schnabel director C/O CREDIT SUISSE FIRST BOSTON, 11 MADISON AVE, NEW YORK NY 10010
Brian K Roberts director DIGITAS INC.,, 800 BOYLSTON STREET, BOSTON MA 02199
Zachary William Stassen officer: Chief Financial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058

ViewRay Headlines

From GuruFocus

Q1 2021 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2021 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2020 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

ViewRay Inc Clinical Data Update Call Transcript

By GuruFocus Research 02-15-2024

Q3 2022 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

ViewRay Inc Investor Day Transcript

By GuruFocus Research 02-15-2024

Q3 2019 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2020 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024